You are hereWP7: Molecular, ECG, genetic aspects
WP7: Molecular, ECG, genetic aspects
- To describe the pharmacokinetic parameters of importance for QT /TdP liability of all study drugs.
- To predict pro-arrhythmia based on the affinity of study drugs for cardiac Na, K and Ca channels (in silico modelling).
- To identify novel electrophysiological parameters for predicting TdP.
- To examine associations between 50,000 genetic polymorphisms in CVD risk genes in cases and controls using a targeted (Illumina) SNP array.To assess the interaction between drug use and 50,000 CVD specific polymorphisms in the case-control studies